ID: ALA3086089

Max Phase: Preclinical

Molecular Formula: C19H19N5O2

Molecular Weight: 349.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1ccc(Nc2ccc(Oc3nccnc3N3CCOCC3)cc2)nc1

Standard InChI:  InChI=1S/C19H19N5O2/c1-2-8-20-17(3-1)23-15-4-6-16(7-5-15)26-19-18(21-9-10-22-19)24-11-13-25-14-12-24/h1-10H,11-14H2,(H,20,23)

Standard InChI Key:  VGCLMLVSRISONU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 349.39

Molecular Weight (Monoisotopic): 349.1539

AlogP: 3.24

#Rotatable Bonds: 5

Polar Surface Area: 72.40

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.05

CX LogP: 2.93

CX LogD: 2.91

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.76

Np Likeness Score: -1.73

References

1. Hu E, Kunz RK, Chen N, Rumfelt S, Siegmund A, Andrews K, Chmait S, Zhao S, Davis C, Chen H, Lester-Zeiner D, Ma J, Biorn C, Shi J, Porter A, Treanor J, Allen JR..  (2013)  Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A).,  56  (21): [PMID:24102193] [10.1021/jm401234w]

2.  (2014)  Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors, 

Source

Source(2):

• Scientific Literature
• BindingDB Database